Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Almost 13 Million Americans Per Year Skip Meds Due to CostAssistance Dogs Bring Big Boost to Deaf PeopleCDC to Toughen COVID Testing for International TravelersOld Spice, Secret Antiperspirants Recalled Due to BenzeneClinical Trials Are Becoming More Diverse, But There's Still Work To DoRural Hospitals' ERs Just as Effective as Urban Ones: StudyKraft Recalls Powdered Drinks Over Metal, Glass ConcernsVials Found in Lab Contained Vaccine, not Smallpox Virus: CDCAdvances in Care, Impact of COVID Highlights of Latest Cardiologists' MeetingAcross America, Black People Have Worse Health OutcomesVials With Smallpox Labels Found at Vaccine Lab in Pennsylvania: CDCWhite House to Spend Billions to Boost COVID Vaccine SupplyAHA News: Health Class May Influence Heart Risk in South AsiansPfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor CountriesFederal Court Backs Stay on COVID Vaccine Mandate for Large BusinessesMore Than 2 Million COVID Home Test Kits Recalled Due to False Positive ResultsIn Canada, Ban on Menthol Cigarettes Had More Smokers QuittingOklahoma Supreme Courts Overturns $465 Million J & J Opioid RulingPandemic Puts 'Outdated' Infection Control Practices Under ScrutinyMillions of Tons of COVID Masks, Gloves Will End Up in OceansSales of Unproven, Unapproved Stem Cell Therapies Are BoomingCourt Temporarily Blocks Biden’s Vaccine Mandate for Big BusinessesU.S. Reopens Borders to Vaccinated Foreign TravelersIt's Time to Replace Your Smoke Alarm BatteriesAHA News: How Doctors Can Help Their Patients Make Heart-Healthy Lifestyle ChangesWhite House Sets Jan. 4 Deadline for Large, Private U.S. Companies to Mandate VaccinesHepatitis B Shots Advised for All U.S. Adults Under 60Supply Chain Issues Bring Shortages of Drugs, Devices to U.S. HospitalsMedicare Could Negotiate Drug Prices Under Democrat ProposalWe've Been Here Before: How Polio Vaccine Rollout Saved Millions of Young LivesAlmost 1 in 3 U.S. Seniors Now Sees at Least 5 Doctors Per YearLanguage Can Make the Difference Between Home, Hospital Care: StudyAttorneys General Warn About Pot Products That Look Like Halloween TreatsCDC Lowers Threshold for Lead Poisoning in Youngest KidsStronger Breast Implant Safety Measures Announced by FDAWalmart Recalls Room Spray for Rare Bacteria That Sickened 4, Killing 2U.S. Gun Violence Rates Jumped 30% During PandemicMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyU.S. Has Shared 200 Million Shots With Other CountriesLittle Change Seen in Americans' Use of Mental Health Services During PandemicWomen Doctors Face Higher Levels of Harassment, Frustration: SurveyEPA Plans New Strategy Against PFAS 'Forever Chemicals'State Spending on Poverty Really Pays Off for Kids: StudyState Lotteries Didn't Help Boost Vaccination RatesVaccinated Foreign Travelers Can Enter United States Beginning Nov. 8Despite Pressures of Pandemic, U.S. Nursing School Enrollment ClimbsBiden Administration to Invest $100 Million to Ease Health Worker ShortageFDA Warns Against Using At-Home Dermal Filler 'Pens'Death Threats, Trolling Common for Scientists Who Speak to Media About COVID'Extreme Heat' Days Have Tripled Since 1980s, and More Are Coming
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Oklahoma Supreme Courts Overturns $465 Million J & J Opioid Ruling

HealthDay News
by Robert Preidt and Robin Foster
Updated: Nov 10th 2021

new article illustration

WEDNESDAY, Nov. 10, 2021 (HealthDay News) -- A previous court ruling that ordered Johnson & Johnson to pay Oklahoma $465 million for the company's role in the opioid epidemic was tossed out by the state's highest court on Tuesday.

In a 5-1 vote, the Oklahoma Supreme Court rejected the state's argument that Johnson & Johnson violated "public nuisance" laws by overstating the benefits of its prescription opioid painkillers and minimizing the dangers, The New York Times reported.

"Oklahoma public nuisance law does not extend to the manufacturing, marketing and selling of prescription opioids," the judges wrote in Tuesday's majority opinion, the Times reported. The judges also gave weight to the company's response that it had not promoted its products in recent years and had sold off one of its product lines in 2015. The judges decided that opioid manufacturers could not be held "perpetually liable" for their products.

It's not clear how the decision to overturn the 2019 ruling will affect similar cases nationwide, since most public nuisance laws are state-specific. A similar opinion by a California state judge was issued on Nov. 1, and the two rulings together could suggest that plaintiffs suing opioid manufacturers, distributors and retailers could be rebuffed in future cases.

Federal data shows the abuse of opioids has contributed to the deaths of some 500,000 Americans since the late 1990s, and the toll has worsened during the pandemic, the Times said.

The decision is disappointing but the state is "still pursuing our other pending claims against opioid distributors who have flooded our communities with these highly addictive drugs for decades," Oklahoma Attorney General John O'Connor told the Times.

Teva, Purdue and other opioid manufacturers that were sued by Oklahoma settled their cases before the trial against Johnson & Johnson began in May 2019, and this new decision does not affect those agreements.

In a statement, Johnson & Johnson said the Oklahoma State Supreme Court decision shows that the company's "marketing and promotion of these important prescription pain medications were appropriate and responsible and did not cause a public nuisance."

Elizabeth Burch, a law professor at the University of Georgia, told the Times that the Oklahoma and California decisions may not predict the fate of other cases winding their way through courts. But the rulings could influence plaintiffs' response to Johnson & Johnson's major national settlement offer in July, when it proposed to pay $5 billion over nine years to resolve all opioid litigation against it.

"If I was a plaintiff that was on the fence about whether to enter the J&J settlement, this ruling might push me closer to settling, if I was risk-averse," Burch said.

More information

Visit the National Institute on Drug Abuse for more on opioids.


SOURCE: The New York Times




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net